Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.
Contineum Therapeutics Price Performance
Shares of CTNM traded down $0.31 during trading hours on Friday, reaching $7.59. The stock had a trading volume of 65,650 shares, compared to its average volume of 71,119. Contineum Therapeutics has a 12 month low of $7.04 and a 12 month high of $22.00. The firm has a 50-day simple moving average of $11.67 and a 200 day simple moving average of $15.22.
Analyst Ratings Changes
Separately, Royal Bank of Canada reaffirmed an "outperform" rating and set a $31.00 price objective on shares of Contineum Therapeutics in a report on Thursday, January 9th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Contineum Therapeutics presently has a consensus rating of "Buy" and an average price target of $29.25.
Read Our Latest Research Report on CTNM
About Contineum Therapeutics
(
Get Free Report)
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Featured Stories
Before you consider Contineum Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Contineum Therapeutics wasn't on the list.
While Contineum Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
